US President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the US. Pharmaceutical companies Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi will now rein in Medicaid drug prices to match what they charged in other developed countries. As part of the deal, new drugs made by those companies will also be charged at the so-called most-favoured-nation pricing across the country on any newly launched medications for all, including commercial and cash pay markets as well as Medicare and Medicaid. Drug prices for patients in the US can depend on a number of factors, including the competition a treatment faces and insurance coverage. Most people have coverage through work, the individual insurance market or government programs like Medicaid and Medicare, which shield them from much of the cost. Patients in Medicaid, the state and federally funded program for peopl